Table 4.
Results of measurement of the plasma putative metabolite panel, CA125 or Both in the diagnosis of early-stage ovarian cancer from benign ovarian tumor.
| Heading | Discovery Set | Validation Set | |||||
|---|---|---|---|---|---|---|---|
| AUC | Cutoff | Sensitivity | Specificity | AUC | Sensitivity | Specificity | |
| Benign vs. Malignant (borderline + malignant) (Plasma) | |||||||
| 5-Meta | 0.847 | 0.72 | 80.77% | 62.86% | 0.988 | 100% | 78.57% |
| CA125 | 0.733 | 35 | 69.23% | 65.71% | 0.893 | 83.33% | 71.43% |
| 5-Meta + CA125 | 0.922 | 0.71 | 80.77% | 91.43% | 1 | 100% | 92.86% |
Abbreviations: 5-Meta, plasma putative metabolite panel.